SCHLAGWORTE: Impact Life Sciences
German biotechnology needs a tailwind
Biotechnology is one of the most promising key industries – with the potential to achieve medical breakthroughs, establish new production processes and shape a...
Heading for clinical breakthrough backed by a broad investor base
Tubulis wants to improve the efficacy of cancer therapies by using antibody drug conjugates (ADCs). Three pipeline products are currently in clinical development. ‘We...
Europe’s shot at radiopharmaceutical leadership
The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory momentum, and investor confidence, this once-niche field is now positioned to...
‘Be patient, but persistent!’
Ghazaleh Madani, CEO of the biotech start-up CanChip, which was founded in 2023, says she is on a mission to revolutionise cancer research with...
Building microbial consortia
mbiomics, based in Neuried near Munich, is pursuing an innovative ‘microbiome engineering’ approach. The company leverages state-of-the-art analytical techniques to precisely develop bacterial consortia...
Hightech meets animal health
The animal health market is booming – and it’s quickly emerging as an attractive
investment opportunity for venture capital firms. Two portfolio companies backed
by MIG...
The right consortium makes all the difference
Telling a catchy equity story and starting to address different investor groups at an early company development stage – how European life sciences companies...
Special issue ‚Life Sciences‘ now online!
Our first special issue 'Life Sciences' features a cover interview with Ghazaleh Madani, founder of CanChip. She was awarded the German Startup Award as...
ASTRA Therapeutics sichert sich Seed-Finanzierung
Die 2022 gegründete ASTRA Therapeutics AG hat sich erfolgreich eine Seed-Finanzierung in Höhe von 7,75 Mio. CHF gesichert! MIG Capital investiert dabei gemeinsam mit Digitalis...
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue...
Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase 1 clinical trial...
‘Germany plays a leading role in radiopharmaceutical therapy’
As the global demand for targeted cancer therapies increases, Germany is emerging as a powerhouse of radiopharmaceutical research and innovation. Playing a leading role...
Now online: Second issue of „Impact Life Sciences“
In this issue's cover interview, Dr Andrew Cavey, CEO of ITM Isotope Technologies Munich SE, shares his views on Germany’s position as a biotech...
Nuclear medicine on the rise
Nuclear medicine is currently experiencing a dynamic resurgence, fuelled by groundbreaking innovations in theranostics, the rapid development of novel radiotracers, and the emergence of...
The use of AI in clinical trials
When using AI in clinical trials, stakeholders point to the challenges associated with the use of AI in clinical trials, amongst others the need...
‘Germany has enormous potential in terms of basic research’
Life sciences expert Dr Achim Plum has been on the management team of High-Tech Gründerfonds (HTGF) since January 2025, strengthening the life sciences sector...